SCHEMBL805864

SCHEMBL805864

O=Cc1cccc(-c2ccc(O)cc2)n1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.64
POLB P06746 2/20 0.64
ALDH1A1 P00352 1/20 0.64
HPGD P15428 1/20 0.64
HSD17B10 Q99714 1/20 0.64
AR P10275 1/20 0.44
MEN1 O00255 7/20 0.42
KMT2A Q03164 7/20 0.42
NTSR1 P30989 1/20 0.42
ESR1 P03372 2/20 0.41
ESR2 Q92731 1/20 0.41
HSD11B1 P28845 1/20 0.40
BCHE P06276 1/20 0.40
RAB9A P51151 3/20 0.39
ALDH5A1 P51649 1/20 0.39
ABAT P80404 1/20 0.39
HSD17B1 P14061 1/20 0.38
HSD17B2 P37059 1/20 0.38
LTA4H P09960 1/20 0.38
MKNK1 Q9BUB5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27972544 0.83 MEN1 (0.56) MAPTPOLBALDH1A1HPGDHSD17B10
SCHEMBL1359228 0.82 MEN1 (0.60) MAPTPOLBALDH1A1HPGDHSD17B10
SCHEMBL3499447 0.81 TERT (0.49) MAPTPOLBALDH1A1HPGDHSD17B10
SCHEMBL2321964 0.81 SMN1; SMN2 (0.41) MAPTPOLBALDH1A1HPGDHSD17B10
SCHEMBL1914634 0.81 TERT (0.49) MAPTPOLBALDH1A1HPGDHSD17B10
SCHEMBL805886 0.81 MAPT (0.64) MAPTPOLBALDH1A1HPGDHSD17B10
SCHEMBL30598255 0.81 TERT (0.49) MAPTPOLBALDH1A1HPGDHSD17B10
SCHEMBL30598256 0.81 TERT (0.49) MAPTPOLBALDH1A1HPGDHSD17B10
SCHEMBL19244573 0.81 MAPT (0.70) MAPTPOLBALDH1A1HPGDHSD17B10
SCHEMBL20339278 0.81 RARA (0.49) POLBALDH1A1RAB9ANPC1ERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2616441-B1 PYRIDINE COMPOUNDS AND THE USES THEREOF PURDUE PHARMA LP (US) 2019-08-07 EP disclosed
US-9611222-B2 Pyridine compounds and the uses thereof PURDUE PHARMA L.P. (US) 2017-04-04 US disclosed
US-20150259293-A1 PYRIDINE COMPOUNDS AND THE USES THEREOF PURDUE PHARMA L.P. 2015-09-17 US disclosed
US-20150259293-A1 PYRIDINE COMPOUNDS AND THE USES THEREOF PURDUE PHARMA L.P. 2015-09-17 US disclosed
US-9056832-B2 Pyridine compounds and the users thereof PURDUE PHARMA L.P. (US) 2015-06-16 US disclosed
US-9056832-B2 Pyridine compounds and the users thereof PURDUE PHARMA L.P. (US) 2015-06-16 US disclosed
US-20130303526-A1 Pyridine Compounds and the Uses Thereof PURDUE PHARMA L.P. (US) 2013-11-14 US disclosed
US-20130303526-A1 Pyridine Compounds and the Uses Thereof PURDUE PHARMA L.P. (US) 2013-11-14 US disclosed
WO-2012035421-A2 PYRIDINE COMPOUNDS AND THE USES THEREOF PURDUE PHARMA L.P. (US) 2012-03-22 WO disclosed
WO-2009148004-A1 NOVEL COMPOUND AND PHARMACEUTICAL APPLICATION OF SAME 株式会社 三和化学研究所 (JP) 2009-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150259293-A1 PYRIDINE COMPOUNDS AND THE USES THEREOF TRPV1, CACNA1A, KCNA1 MAPT 3114/4885POLB 4705/4885ALDH1A1 172/4885
US-20130303526-A1 Pyridine Compounds and the Uses Thereof TRPV1, CACNA1A, KCNA1 MAPT 3114/4885POLB 4705/4885ALDH1A1 172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.